Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
作者信息
Bogenberger James M, Delman Devora, Hansen Nanna, Valdez Riccardo, Fauble Veena, Mesa Ruben A, Tibes Raoul
机构信息
Department of Hematology and Oncology, Mayo Clinic , Scottsdale, AZ , USA.
出版信息
Leuk Lymphoma. 2015 Jan;56(1):226-9. doi: 10.3109/10428194.2014.910657. Epub 2014 Jun 17.
Abstract
摘要
相似文献
1
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Leuk Lymphoma. 2015 Jan;56(1):226-9. doi: 10.3109/10428194.2014.910657. Epub 2014 Jun 17.
2
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.
3
ABT-199 partners with azacitidine to contest myeloid malignancies.
Leuk Lymphoma. 2015 Jan;56(1):8-9. doi: 10.3109/10428194.2014.919638. Epub 2014 Jul 15.
4
Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Br J Pharmacol. 2016 Feb;173(3):471-83. doi: 10.1111/bph.13370. Epub 2016 Jan 16.
5
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Cell Death Differ. 2019 Jul;26(7):1316-1331. doi: 10.1038/s41418-018-0209-1. Epub 2018 Nov 23.
6
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.
7
Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.
Leuk Lymphoma. 2018 Oct;59(10):2447-2453. doi: 10.1080/10428194.2018.1434884. Epub 2018 Feb 12.
8
Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
Pharmacol Res. 2019 Apr;142:87-100. doi: 10.1016/j.phrs.2019.01.040. Epub 2019 Feb 3.
9
Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters.
Pharmazie. 2017 Dec 1;72(12):751-758. doi: 10.1691/ph.2017.7696.
10
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.
引用本文的文献
1
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.
Nat Rev Clin Oncol. 2025 Sep 1. doi: 10.1038/s41571-025-01068-0.
2
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review.
Front Oncol. 2025 Aug 8;15:1644661. doi: 10.3389/fonc.2025.1644661. eCollection 2025.
3
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.
Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.
4
Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia.
Eur J Med Res. 2025 Apr 26;30(1):330. doi: 10.1186/s40001-025-02571-x.
5
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days.
Blood Cancer J. 2025 Apr 3;15(1):56. doi: 10.1038/s41408-025-01270-4.
6
Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.
Front Immunol. 2025 Feb 26;16:1525110. doi: 10.3389/fimmu.2025.1525110. eCollection 2025.
7
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.
Heliyon. 2024 Dec 19;11(1):e41355. doi: 10.1016/j.heliyon.2024.e41355. eCollection 2025 Jan 15.
8
Getting the right combination to break the epigenetic code.
Nat Rev Clin Oncol. 2025 Feb;22(2):117-133. doi: 10.1038/s41571-024-00972-1. Epub 2024 Dec 2.
9
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.
Blood Cancer Discov. 2025 Jan 8;6(1):23-37. doi: 10.1158/2643-3230.BCD-24-0171.
10
Enhancement of the Sensitivity of the Acute Lymphoblastic Leukemia Cells to ABT-737 by Formononetin.
Int J Mol Cell Med. 2024;13(3):259-271. doi: 10.22088/IJMCM.BUMS.13.3.259.
本文引用的文献
1
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.
2
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.
3
Mitochondria: gatekeepers of response to chemotherapy.
Trends Cell Biol. 2013 Dec;23(12):612-9. doi: 10.1016/j.tcb.2013.08.003. Epub 2013 Sep 21.
4
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. Epub 2013 Jan 17.
5
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.
6
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.
Genes Dev. 2012 Jan 15;26(2):120-5. doi: 10.1101/gad.182980.111.
7
Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.
Blood. 2009 Feb 12;113(7):1522-5. doi: 10.1182/blood-2008-03-143321. Epub 2008 Dec 5.
8
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Cancer Cell. 2006 May;9(5):351-65. doi: 10.1016/j.ccr.2006.03.027.
9
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.
Science. 2005 Feb 18;307(5712):1101-4. doi: 10.1126/science.1106114.
10
Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.
N Engl J Med. 1998 Feb 26;338(9):564-71. doi: 10.1056/NEJM199802263380902.
Zotero 插件